Girard Philippe, Verniers Danielle, Pansart Yannick, Gillardin Jean-Marie
Biocodex, Service de Pharmacologie, Zac de Mercières 60200 Compiègne, France.
Can J Physiol Pharmacol. 2007 May;85(5):556-61. doi: 10.1139/y07-042.
The potent antidepressant effect of moclobemide, a selective and reversible type A monoamine oxidase (MAO) inhibitor, is clinically established. In view of the ongoing debate on the neuroprotective properties of MAO inhibitors, the present study was undertaken to further define the protective effect of moclobemide in a rat model of neurotoxicant-induced edema. In this model, daily oral triethyltin (TET) administration for 5 consecutive days strongly perturbed the rat behaviour and induced a cerebral edema at the 5th day. Oral coadministration of moclobemide (2 x 100 mg.kg-1.day-1) with TET blocked the development of brain edema and the increase in the cerebral chloride content induced by TET. Moreover, moclobemide reduced the increase in the cerebral sodium content and attenuated the neurological deficit. In conclusion, moclobemide possesses potent protective properties in this rat model of cerebral edema, suggesting potential clinical utility as a neuroprotectant.
选择性可逆A型单胺氧化酶(MAO)抑制剂吗氯贝胺的强效抗抑郁作用已得到临床证实。鉴于目前关于MAO抑制剂神经保护特性的争论,本研究旨在进一步明确吗氯贝胺在神经毒物诱导的水肿大鼠模型中的保护作用。在该模型中,连续5天每日口服三乙锡(TET)会严重干扰大鼠行为,并在第5天诱发脑水肿。吗氯贝胺(2×100 mg·kg-1·天-1)与TET联合口服可阻止脑水肿的发展以及TET诱导的脑氯含量增加。此外,吗氯贝胺可降低脑钠含量的增加并减轻神经功能缺损。总之,吗氯贝胺在该脑水肿大鼠模型中具有强大的保护特性,提示其作为神经保护剂具有潜在的临床应用价值。